Results 161 to 170 of about 29,315 (207)
Bilateral Adrenal Hemorrhage After Laminectomy: A Rare Complication. [PDF]
JCEM Case RepSharma S +4 more
europepmc +1 more source
The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease [PDF]
, 2019 et al, +2 more
core +1 more source
Spontaneous Heparin-Induced Thrombocytopenia Following Orthopedic Surgery. [PDF]
CureusKorolyov A, Hu R.
europepmc +1 more source
Cerebral venous sinus thrombosis as a complication of heparin-induced thrombocytopenia in myasthenia gravis: A rare and complex case. [PDF]
Qatar Med JAbuAlrob MA +6 more
europepmc +1 more source
The Role of Long-Range Non-Specific Electrostatic Interactions in Inhibiting the Pre-Fusion Proteolytic Processing of the SARS-CoV-2 S Glycoprotein by Heparin. [PDF]
BiomoleculesDu Y, Yang Y, Nguyen SN, Kaltashov IA.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Eduard Shantsila, Gregory Lip
exaly +3 more sources
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Eduard Shantsila, Gregory Lip
exaly +3 more sources
Drugs of the Future, 2002
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+8 more sources
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+8 more sources
Current Pharmaceutical Design, 2005
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources